Effectiveness and patient satisfaction of a Dutch patient decision aid for psoriasis – a pilot study

Click to increase image sizeClick to decrease image size

Acknowledgments

We would like to thank Michiel Hageman (director of PATIËNT + Netherlands) for the technical development of the PtDA and his input on our paper.

Disclosure statement

AH was involved as sub-investigator in clinical trials for Abbvie, Lilly, LeoPharma and UCB. NR has no conflicts of interest. GK and PS were involved in the development of the PtDA investigated in this study. DU has no conflicts of interest. PS received a departmental independent research grants for TREAT NL registry from Pharma since December 2019 for the TREAT NL registry, is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of e.g. psoriasis and atopic dermatitis, for which financial compensation is paid to the department/hospital and, is Chief Investigator (CI) of the systemic and phototherapy atopic eczema registry (TREAT NL) for adults and children and one of the main investigator of the SECURE-AD registry.

Data availability statement

Our data is available on request. Data will be shared with researchers who provide a methodologically sound proposal after execution of a data-sharing agreement.

Additional information

Funding

For this study, there were no funding sources. The Dutch PtDA (the intervention of our study) was developed with a research grant from the Quality Assurance Medical Specialists Foundation (Stichting Kwaliteitsgelden Medisch Specialisten) which was provided by The Dutch National Society of Dermatology and Venereology (Nederlandse Vereniging voor Dermatologie en Venereologie). The English version of the Dutch Decision Aid Psoriasis was established with a European Academy of Dermatology and Venereology research grant.